{"id":"W4385949824","doi":"10.3389/fonc.2023.1223282","title":"Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms","year":2023,"lang":"en","type":"article","venue":"Frontiers in Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"ca_institutions":"Western University","funders":"National Cancer Institute; Eisai; Memorial Sloan-Kettering Cancer Center","keywords":"Lenvatinib; Medicine; Sunitinib; Pembrolizumab; Renal cell carcinoma; Internal medicine; Oncology; Kidney cancer; Everolimus; Nephrectomy; Urology; Sorafenib; Cancer; Kidney; Immunotherapy; Hepatocellular carcinoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003729369,0.001212581,0.002564246,0.0004789853,0.0005367885,0.001005218,0.0007823044,0.00106549,0.002562343],"category_scores_gemma":[0.001434868,0.0004927872,0.003248053,0.0005430119,0.0007197734,0.001066205,0.0006837695,0.002460371,0.0005913444],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007599783,"about_ca_system_score_gemma":0.002108842,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007785162,"about_ca_topic_score_gemma":0.002204539,"domain_scores_codex":[0.9985898,0.0007593035,0.00009300035,0.0002194534,0.000176473,0.0001620738],"domain_scores_gemma":[0.9985597,0.000205704,0.0003817811,0.0001283306,0.0001042612,0.0006202376],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9241967,0.01224924,0.02816182,0.0004916815,0.003537996,0.00009844195,0.0001377413,0.001085356,0.009511454,0.0001492218,0.001587754,0.01879261],"study_design_scores_gemma":[0.6255012,0.2602608,0.1036556,0.00006746279,0.002475391,0.0003086044,0.0001371143,0.001594232,0.002153156,0.0004520842,0.003337296,0.00005696893],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9920964,0.002565323,0.000318911,0.000309732,0.00007232364,0.001856447,0.001721112,0.00002872874,0.001030937],"genre_scores_gemma":[0.9881932,0.0009953544,0.001145315,0.0007358528,0.0002213098,0.00309502,0.004599657,0.0000217354,0.0009925291],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003729369,"threshold_uncertainty_score":0.01972306,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02308070190058515,"score_gpt":0.3056554367024069,"score_spread":0.2825747348018217,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}